AstraZeneca’s Dato-DXd BLA Accepted for Priority Review (AZN: NASDAQ)


The FDA has accepted AstraZeneca (NASDAQ:AZN) and Daiichi Sankyo’s biologics license application for priority review of its drug datopotamab deruxtecan, also known as Dato-DXd, for the treatment of EGFR-mutated lung cancer.

Companies seek to have Dato-DXd approval



Source link

  • Related Posts

    StubHub launches sports ticketing platform exclusively for women

    See what’s clicking on FoxBusiness.com. In honor of Women’s History MonthStubHub is jumping on the bandwagon of women’s sports and its continued growth. The ticketing platform announced Tuesday that they…

    Client Challenge

    Client Challenge JavaScript is disabled in your browser. Please enable JavaScript to continue. A required part of this site could not load. This could be due to a browser extension,…

    Leave a Reply

    Your email address will not be published. Required fields are marked *